PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines for rare disorders in neurology and metabolism. Its commercial portfolio includes Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza (marketed as Kebilidi in the United States) for AADC deficiency. The company also holds rights to Tegsedi and Waylivra for hereditary transthyretin amyloidosis and familial chylomicronemia syndrome in Latin America and the Caribbean, and Evrysdi for spinal muscular atrophy through a collaboration with Roche. PTC Therapeutics maintains a development pipeline featuring votoplam for Huntington’s disease, which is being advanced in partnership with Novartis, and vatiquinone for Friedreich’s ataxia. The company operates scientific platforms in splicing and inflammation/ferroptosis to address unmet medical needs in pediatric and adult populations.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ptcbio.com
Sector Healthcare IR page ptcbio.com
Tags
rare diseases, neurology, metabolism, gene therapy, splicing modifiers, duchenne muscular dystrophy, phenylketonuria, spinal muscular atrophy, huntington's disease, friedreich's ataxia, Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Tegsedi, Waylivra, Evrysdi, votoplam, vatiquinone
Press page —

Metrics

Valuation  
Market cap $ 5.193B
Market cap (USD) $ 5.193B
P/E -45.71
PEG —
P/BV -27.16
P/S 4.49
P/OCF 495.22
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -332.5%
ROI 32.4%
ROIC 40.3%
Profit margin 39.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 55
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 1.731B 806.78M 937.822M 698.801M 538.593M 380.766M 306.98M 264.734M 194.392M 82.705M 36.766M 25.245M 34.696M 33.946M
Net profit 682.644M -363.295M -626.604M -559.017M -523.901M -438.16M -251.576M -128.081M -79M -142.11M -170.447M -93.753M -51.574M -26.235M
Free cash flow 702.336M -114.19M -186.856M -388.67M -279.545M -211.914M -112.396M -34.738M -13.164M -105.342M -127.057M -61.938M -47.768M -48.116M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 75.96 45.14 27.56 38.17 39.83 61.03 48.03 34.32 16.68 10.91 32.4 51.77 16.97 —
Price performance 12m 0.68 0.64 -0.28 -0.04 -0.35 0.27 0.4 1.06 0.53 -0.66 -0.37 2.05 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 24.9M 40.4M 67.9M 55.5M 69.9M 110M 156M 161M 159M 182M
↳ YoY growth +124.7% +62.0% +68.1% -18.2% +25.9% +58.0% +40.9% +3.3% -1.4% +14.5%
↳ 5y CAGR +134.5% +65.7% +44.5% +34.7% +31.0% +18.8% +23.3% +21.0%
Borrowings, current (USD) — 0.00 11.7M 20M — 150M — — — 287M
Borrowings, non-current (USD) 98.2M 145M 141M 294M 309M 282M 572M 284M 285M —
Lease liabilities (USD) — — 11.3M 14.2M 111M 104M 132M 131M 104M 112M
Cash and deposits (USD) 58.3M 112M 169M 288M 209M 190M 280M 594M 780M 985M
Intangible assets (USD) 0.00 133M 701M 711M 715M 725M 706M 379M 119M 389M
Right-of-use assets (USD) — — 11.3M 13.7M 84.4M 77.4M 102M 91.9M 56.7M 80.1M
Net debt (borrowings + leases - cash) (USD) 39.9M 33.2M -16.5M 40M 212M 346M 424M -179M -390M -586M
Cash flow detail
Operating cash flow (USD) -104M -10.1M -27.6M -98.6M -194M -251M -357M -158M -108M 711M
Purchases of property, plant and equipment (USD) -1.78M -3.1M -7.1M -13.8M -17.8M -28.2M -32M -28.4M -6.5M -8.86M
Purchases of intangible assets (USD) 0.00 -77.2M -8.43M -31.7M -38.1M -57.1M -120M -92.2M -67.7M -291M
Change in receivables (cash effect) (USD) -14.8M -12.2M -29.6M 11.5M -10.5M -45M -48.5M -1.54M 1.73M -10.2M
Change in inventories (cash effect) (USD) 0.00 -6.45M -5.82M -3.46M 1.84M 1.8M -6.67M -8.18M 6.16M -53.9M
Change in payables (cash effect) (USD) 4.26M 24M 43.9M 26.8M 70.8M 45.7M 27.5M 48.3M -33.3M 71.7M
Interest paid (cash effect) (USD) -4.51M -6.27M -7.77M -7.69M -9.8M -9.59M -18.5M -36.1M -5.82M -5.7M
Income taxes paid (cash effect) (USD) -943,000 -1.1M -1.58M -2.11M -26.4M -7.71M -4.92M -14.2M -17.6M -36.9M
Share-based compensation (USD) 35M 30.6M 33.3M 42.1M 70.3M 104M 110M 102M 74.6M 74.5M
Operating cash flow before change in receivables (USD) -88.7M 2.14M 1.95M -110M -184M -206M -308M -157M -109M 721M
Free cash flow (OCF - PPE - intangibles) (USD) -105M -90.3M -43.2M -144M -250M -337M -509M -279M -182M 411M
Income detail
Research and development expense (USD) 118M 117M 172M 257M 478M 541M 651M 667M 534M 455M
↳ 5y CAGR +14.9% +20.5% +25.7% +26.4% +31.4% +35.7% +40.9% +31.1% +15.7% -1.0%
Total comprehensive income (USD) -142M -73.5M -131M -264M -489M -487M -530M -633M -388M 719M
Comprehensive income to owners (USD) -142M -73.5M -131M -264M -489M -487M -530M -633M -388M 719M
Provision for credit losses (USD) — — — — — 100,000 200,000 900,000 1.7M 12.2M
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.1% 0.2% 0.6% 1.1% 7.2%
Reported Mar 6, 2018 Aug 7, 2018 Mar 2, 2020 Mar 2, 2020 Feb 25, 2021 Feb 29, 2024 Feb 29, 2024 Feb 29, 2024 Feb 27, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026

PDF Version

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.

"The share repurchase program reflects our deep conviction in the strength of the Company and the prospects for near- and long-term growth," said Matthew B. Klein, M.D., Chief Executive Officer. "We are investing in PTC at a time when our shares provide a compelling opportunity while still maintaining the financial flexibility to support existing programs and pursue potential value creative business development transactions."

Under the authorization, share repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.

About PTC Therapeutics, Inc.

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.

November 2, 2026

PDF Version

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTC Therapeutics, Inc. Logo

Jefferies Global Healthcare Conference****Monday, Nov. 16 at 11 a.m. GMT/6 a.m. ET

Citi 2026 Global Healthcare Conference****Tuesday, Dec. 1 at 9:40 a.m. ET

The presentations will be webcast live on the Events and Presentations page under the Investor section of the PTC Therapeutics website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.

About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook and Instagram.

October 30, 2026

PDF Version

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

PTC Therapeutics, Inc. Logo

The inducement grants were approved by PTC's Compensation Committee on Oct. 28, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $63.02 per share, the closing price of PTC's common stock on Oct. 28, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.

Prompts

PTC Therapeutics, Inc. (ticker PTCT), listed in United States.

ETFs Holding PTC Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
HELX 1.46% 5,009 $ 408.584K Jun 30, 2026
MEDI 1.40% 9,930 $ 629.165K Nov 12, 2026
JSML 1.03% 54,825 $ 3.729M Jul 31, 2026
JSMD 0.94% 145,033 $ 9.864M Jul 31, 2026
VAMO 0.72% 11,494 $ 781.707K Jul 31, 2026
SHRT 0.60% 1,262 $ 76.944K Nov 17, 2026
FSCC 0.56% 29,287 $ 2.037M Aug 31, 2026
MMSC 0.54% 4,420 $ 269.487K Nov 16, 2026
JDOC 0.48% 790 $ 47.684K Nov 17, 2026
PSC 0.47% 135,289 $ 11.036M Jun 30, 2026
SEIS 0.46% 32,973 $ 2.69M Jun 30, 2026
BMED 0.43% 1,001 $ 61.031K Nov 16, 2026
FSEG 0.39% 273 $ 22.269K Jun 30, 2026
OASC 0.37% 5,029 $ 349.717K Aug 31, 2026
RUSC 0.36% 3,528 $ 287.779K Jun 30, 2026
MSSM 0.34% 35,068 $ 2.439M Aug 31, 2026
ESSC 0.34% 1,785 $ 121.398K Jul 31, 2026
FTKI 0.32% 1,342 $ 81.822K Nov 16, 2026
GVLU 0.22% 9,253 $ 564.155K Nov 17, 2026
FESM 0.22% 154,723 $ 12.621M Jun 30, 2026
SAGP 0.22% 2,036 $ 166.077K Jun 30, 2026
RESM 0.21% 93 $ 7,586.01 Jun 30, 2026
AFSM 0.18% 4,412 $ 269K Nov 16, 2026
FELV 0.17% 68,425 $ 5.581M Jun 30, 2026
MKTN short -0.15% -1,993 $ -162.569K Jun 30, 2026
FHEQ 0.14% 18,636 $ 1.267M Jul 31, 2026
FSEV 0.13% 105 $ 8,564.85 Jun 30, 2026
SMDX 0.12% 2,417 $ 147.364K Nov 17, 2026
FYEE 0.11% 3,600 $ 244.836K Jul 31, 2026
SCDS 0.10% 155 $ 9,355.80 Nov 17, 2026
FSML 0.10% 1,501 $ 122.437K Jun 30, 2026
FELC 0.08% 79,357 $ 6.473M Jun 30, 2026
FTLS 0.07% 31,262 $ 0.00 Nov 16, 2026
VFMO 0.05% 14,769 $ 1.027M Aug 31, 2026
DFAS 0.05% 281,221 $ 17.818M Nov 12, 2026
FEAC 0.05% 162 $ 13.214K Jun 30, 2026
IALT short -0.03% -34,508 $ -2.104M Nov 16, 2026
DFAC 0.01% 149,386 $ 9.465M Nov 12, 2026
AVSU 0.01% 506 $ 30.851K Nov 16, 2026
AVUQ 0.01% 482 $ 29.388K Nov 16, 2026
DFUS 0.01% 32,283 $ 2.045M Nov 12, 2026
DCOR 0.01% 48,039 $ 3.044M Nov 12, 2026
DFAU 0.00% 3,158 $ 200.091K Nov 12, 2026
FELG 0.00% 6 $ 489.42 Jun 30, 2026